ClinicalTrials.Veeva

Menu

First-line Chemotherapy for Recurrent Cervical Cancer

L

Lei Li

Status and phase

Completed
Phase 2

Conditions

Targeted Therapy
Chemotherapy
Vascular Endothelial Growth Factor 2 Inhibitor
Persistent Advanced Cervical Carcinoma
Recurrent Cervical Carcinoma
Apatinib

Treatments

Drug: Chemotherapy plus apatinib

Study type

Interventional

Funder types

Other

Identifiers

NCT04188847
REPACC-1

Details and patient eligibility

About

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or partial remission, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

Enrollment

37 patients

Sex

Female

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female of 18-75 years old
  • Eastern Cooperative Oncology Group score 0-1
  • Pathological confirmed of uterine cervical adenocarcinoma, squamous carcinoma, or adenosquamous carcinoma, with stage IA1 (with lymph-vascular space invasion) to IVB, which had accepted radical treatment for the purpose of cure
  • An interval of 3 months or more since the fulfilling of last treatment
  • At least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST) guideline 1.1
  • Anticipative survival period of 3 months or more
  • Lab testing within reference ranges
  • With appropriate contraception
  • Provided consents of participating the trial

Exclusion criteria

  • With a history of exposure to other antiangiogenic agents
  • With other malignancies within past 3 years
  • With vital complications
  • With uncontrolled hypertension despite of medical treatment
  • With severe cardiac disease, coagulation disorders, bleeding disorders, vascular diseases, deep venous thrombosis
  • With brain metastasis
  • With addiction to psychiatric medications or with mental disorders
  • With severe open trauma, fracture or major surgery with past 4 weeks
  • With disorders which would hamper the absorption of oral drugs, or with intestinal perforation or ileus with past 6 months
  • Urine protein ≥++, or 24 hr urine protein ≥1.0 g
  • With potential allergy or intolerance to study regimens
  • Not eligible for the study judged by researchers

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

37 participants in 1 patient group

Study group
Experimental group
Description:
The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
Treatment:
Drug: Chemotherapy plus apatinib

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems